EGFR mutant-selective inhibitor QLH11811

{
  "id": "MLC-T-ONC-013260",
  "term": "EGFR mutant-selective inhibitor QLH11811",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, mutant-selective, fourth-generation epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor QLH11811 targets, binds to and inhibits the activity of EGFR with selective mutations, including ex19del, L858R, T790M and C797S, thereby preventing EGFR mutant-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR mutant-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.",
  "synonyms": [
    "EGFR inhibitor QLH11811"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-mutant-selective-inhibitor-qlh11811/"
}